Latest / CME Outfitters Medical Education / Integrating Clinical Trial Evidence into Global HIV Practice
Transcript
- 0:01SPEAKER_04: Hello and welcome.
- 0:02SPEAKER_04: On behalf of CME Outfitters, I'd like to welcome you and thank you for joining us today.
- 0:08SPEAKER_04: This activity is titled Integrating Clinical Trial Evidence into Global HIV Practice.
- 0:14SPEAKER_04: This program has been supported by an independent educational grant from Gilead Sciences.
- 0:20SPEAKER_04: Today's activity may include discussion of products or uses that are not approved by the FDA or any other relevant regulatory authorities.
- 0:30SPEAKER_04: Faculty will identify investigational or off-label uses when we're discussing them.
- 0:37SPEAKER_04: Reimbursement, public funding, and access pathways do vary by country and they do change frequently.
- 0:43SPEAKER_04: So please consult your local, current national guidance.
- 0:48SPEAKER_04: One additional disclosure before we start.
- 0:51SPEAKER_04: Portions of this presentation's visuals were developed with generative AI assistance.
- 0:56SPEAKER_04: Per CME Alfredur's policy, all information though, was fact-checked against primary sources and reviewed by actual human beings.
- 1:06SPEAKER_04: So I'm David Allenwall.
- 1:09SPEAKER_04: I'm a professor of medicine at the Division of Infectious Diseases at the University of North Carolina, Chapel Hill.
- 1:15SPEAKER_04: And I am truly and sincerely delighted to be joined by three esteemed colleagues who bring not only just their insights, but also, I think, really important global perspectives.
- 1:26SPEAKER_04: So I'm going to introduce and then have them introduce themselves, Dr.
- 1:30SPEAKER_04: Aving Sanam, Dr.
- 1:32SPEAKER_04: Agu Bhagu, and Dr.
- 1:33SPEAKER_04: Orkin.
- 1:34SPEAKER_04: So please introduce yourselves, provide a little bit about your background in HIV, and I'm going to start it off with Dr.
- 1:41SPEAKER_04: Orkin.
- 1:43SPEAKER_03: Thank you so much, David.
- 1:45SPEAKER_03: So my name is Chloe Orkin, and I uh work in London.
- 1:50SPEAKER_03: And I'm a physician scientist, and I do a lot of work around uh new therapies, uh, and particularly around equity and making sure that these drugs are implemented equitably.
- 2:02SPEAKER_04: Thank you.
- 2:03SPEAKER_04: And Dr.
- 2:04SPEAKER_04: Aving Sanon.
- 2:06SPEAKER_02: Hello, I'm uh Anjali Aving Sanon.
- 2:09SPEAKER_02: So I'm the uh infected disease and the director of Kidnap uh at the Taiwanese cross research center in Bangkok, Thailand.
- 2:18SPEAKER_02: So my clinical and research will focus on HIV treatment, treatment optimization, drug resistant, tuberculosis, and viral hepatitis coinfection, and also like a translating clinical trial even into real world practice, particularly in Asia and resource medicine setting.
- 2:40SPEAKER_02: So thank you very much for inviting me to guide this panel.
- 2:44SPEAKER_04: Thank you.
- 2:45SPEAKER_04: It's wonderful to have you.
- 2:46SPEAKER_04: And lastly, Dr.
- 2:48SPEAKER_04: Agbuagu, please introduce yourself.
- 2:51SPEAKER_00: Hello, David, and hello, other panelists, and thank you everyone for joining us today.
- 2:55SPEAKER_00: My name is Unyema Ubuagu.
- 2:57SPEAKER_00: I'm a professor of medicine and pharmacology at Yale School of Medicine.
- 3:01SPEAKER_00: I also direct the Antivirals and Vaccines Research Program, which of course one of our large portfolios is working on novel therapeutics for HIV treatment and prevention.
- 3:11SPEAKER_00: I also do work globally in Liberia and Rwanda supporting HIV programs as well as uh developing research capacity.
- 3:20SPEAKER_04: Great, wonderful.
- 3:21SPEAKER_04: So great team.
- 3:22SPEAKER_04: So let's jump in.
- 3:23SPEAKER_04: So for this CMEO SNAC, we're going to be sampling uh kind of different anti-retroviral combinations that are new and novel and really at the front line of what we're thinking about as the next phase for HIV therapeutics.
- 3:40SPEAKER_04: So to frame our discussion, though, I think it's important for us to just look at our learning objective, which is to evaluate the latest efficacy and safety data from recent, very recent clinical trials for novel and emerging therapies for HIV.
- 3:55SPEAKER_04: And this is going to include the long-acting agents, injectable and not.
- 3:59SPEAKER_04: So we're going to start off with an audience response question.
- 4:03SPEAKER_04: And here it is In your clinical practice, which patient scenario do you encounter most often that could benefit from a long-acting, novel, or emerging HIV regimen?
- 4:34SPEAKER_04: Great.
- 4:35SPEAKER_04: Okay.
- 4:35SPEAKER_04: So now let's dive in.
- 4:37SPEAKER_04: So as we know, uh revolution and HIV care with the integrace inhibitors, they dominate guidelines, as we'll talk about, and they are the backbone now of therapeutics globally.
- 4:53SPEAKER_04: So the world is caught up.
- 4:54SPEAKER_04: It's an integrace world, and we're retreating within it.
- 4:58SPEAKER_04: So that's fantastic.
- 4:59SPEAKER_04: And now what we're seeing is not only that, but we've seen integrace inhibitors be a backbone of three drug regimens.
- 5:06SPEAKER_04: But more and more we're seeing integrace inhibitors be part of two drug regimens.
- 5:11SPEAKER_04: In addition, as we'll talk about, we're starting to move into integrace-free regimens, whether they be two drug or more, but usually two drug.
- 5:20SPEAKER_04: So that's interesting too, and we'll talk about that.
- 5:22SPEAKER_04: But even on the long-acting, you know, injectable or long-acting regimen horizon, we see a mix of integrace and non-integrace-based regimens.
- 5:33SPEAKER_04: So things are moving quickly.
- 5:34SPEAKER_04: So we're going to jump around, you'll see, because there's going to be a lot of hopping back and forth between integrace, non-integrace, long-acting, oral, injectable, because we really have more options than ever before.
- 5:46SPEAKER_04: So I think it's good to take a step back and look at what guidelines have to say.
- 5:51SPEAKER_04: Guidelines have been really important.
- 5:53SPEAKER_04: And we have guidelines from all over the world.
- 5:55SPEAKER_04: We don't have one unifying guideline for the entire planet.
- 5:57SPEAKER_04: And that's important because there's context that has to be understood as well.
- 6:02SPEAKER_04: So looking at the different guidelines, and we've listed some here, whether they be the Department of Health and Human Services and the IAS USA guidelines, which largely align, versus Eeks, which has to have different considerations, as we know, because of the financial and differences between some of the EU countries, Germany, let's say, versus Portugal.
- 6:23SPEAKER_04: While in the US, we seem to be, of course, much more US focused.
- 6:27SPEAKER_04: And then WHO, which does try to be all things to all, understanding that there's got to be some common denominator in the of what we can provide for people living with HIV worldwide.
- 6:38SPEAKER_04: So I'm just going to turn this over to my colleagues to reflect on this because you think about this all the time.
- 6:44SPEAKER_04: So I'll start over with you, Angela, just thinking about the guidelines and how just briefly how much they influence what you do.
- 6:53SPEAKER_02: Yes, I think an important part is that the guidelines are developed for very different healthcare settings.
- 7:01SPEAKER_02: So in individualized care, so we can focus on like uh identifying the best option for each person.
- 7:08SPEAKER_02: But in countries with large national HIV program, so we also need to consider whether a new strategy is affordable, feasible, and scalable.
- 7:19SPEAKER_02: So in Thailand and many parts of Asia, so doing technology-based ART is already highly effective while we use an available at a very low cost as a fixed dose combination.
- 7:34SPEAKER_02: So newer uh regimen need to offer benefits beyond viral suppression, so such as reduce treatment burden, addressing advanced challenges, improve the privacy or quality of life.
- 7:49SPEAKER_02: So these are all providing options for people with more complex treatment needs.
- 7:55SPEAKER_02: So I think uh the challenges is to balance individualized treatment choice with what can the listed delivery within each uh system.
- 8:06SPEAKER_02: So it's different between the US and between Thailand, for example.
- 8:11unknown: Okay.
- 8:12SPEAKER_04: Absolutely, absolutely.
- 8:13SPEAKER_04: Angema, again, I think thinking about guidelines here in the United States, we kind of take it for granted a little bit because we do have the HHS guidelines and they are um, I think, the most aspirational, maybe of all.
- 8:25SPEAKER_04: So, how how does that play out when you think about this here and globally?
- 8:30SPEAKER_00: Yeah, so again, David, as you well know, right, I'm a member of the DHS guidelines panel, but my comments would be mine, and you've been so in the past.
- 8:38SPEAKER_00: So, I mean, first of all, I think the DHS is a great resource for US providers regarding just the universe of you know anti-trial therapy.
- 8:46SPEAKER_00: Um, but we do know that we are a resource for other international, non-US settings, including a place like Australia, I think that adopts our guidelines when we do release them.
- 8:55SPEAKER_00: So we do sometimes uh consider that.
- 8:58SPEAKER_00: But I do agree that we do have the luxury of having every novel agent that emerges available to us.
- 9:04SPEAKER_00: Um, I think that in general, the principles are for DHS guidelines panel, we try to keep fidelity to the clinical trial data that's available, um, and of course, rank according to the evidence that's available to guide whatever we recommend for individuals.
- 9:17SPEAKER_00: But I also think that we are forward thinking and um in in cases where there is data, albeit not gold standard data, but where there could be benefit for patients.
- 9:26SPEAKER_00: And a good example of that will be for cabotech veropevering, which does have a much narrower label.
- 9:31SPEAKER_04: So, speaking of clinical trials, and of course, clinical trials are what really motivate the guidelines and what they recommend, we're gonna go into some different clinical trials, including those that were presented very recently at the International Aid Society meeting that was held in Rio Brazil, and that you all really played a big part of presenting to us.
- 9:52SPEAKER_04: So, one of the first ones I'm gonna uh hit on is the Vogue study.
- 9:58SPEAKER_04: So, this is a study, a trial that looked at Dalutegr 3TC versus Victegravir TAF FTC.
- 10:06SPEAKER_04: And people might say, well, we know about that, but this is in naive folks.
- 10:10SPEAKER_04: These are in people who are naive to treatment and a head-to-head phase three study.
- 10:14SPEAKER_04: And I think this is an important study because again, looking at head-to-head data, we really get a better sense.
- 10:20SPEAKER_04: And this is a study that was done internationally, pretty well powered.
- 10:23SPEAKER_04: And dietavir 3PC versus BFTAF, as I'll call it, as initial therapy, we saw that there was non-inferiority where there was very high-level virologic suppression pushing around 90% in both study arms at week 48.
- 10:37SPEAKER_04: And importantly, and really reassuringly, again, there was no treatment emergent resistance in either arm.
- 10:44SPEAKER_04: And the safety looked really good.
- 10:46SPEAKER_04: So, not huge surprises.
- 10:48SPEAKER_04: And I think if anything buttresses guideline recommendations that we have right now, but I think it is nice to not have to extrapolate and to have a real head-to-head study.
- 10:59SPEAKER_04: So I think this is another example of where clinical trial data can come along and help us and support many of the things that we're doing as well.
- 11:07SPEAKER_04: And so we're gonna move as well into other clinical trials that get into maybe more novel than dietogra 3TC or BFTAF regimens, but including long acting.
- 11:19SPEAKER_04: So let's take another moment right now for an audience response question before we do that.
- 11:24SPEAKER_04: So here we go.
- 11:25SPEAKER_04: When considering an emerging HIV regimen, which type of evidence is most likely to change your clinical practice?
- 11:53SPEAKER_04: So, as promised, um, I'm gonna ask Chloe for her thoughts about um some of the information that we've seen lately, including some older information that she knows really well and some newer data that was recently presented.
- 12:06SPEAKER_04: So we we have quite a bit of experience with cabot temporary rapifarine, as Anima mentioned, it's in the guidelines.
- 12:13SPEAKER_04: Um, but we're getting you know more and more data, including data, legacy data, if you will, from older clinical trials that help put this on the map, and also real-world data.
- 12:23SPEAKER_04: Can you walk us through sort of where we are with our understanding of how cabitarial ripivrine is being used?
- 12:29SPEAKER_03: Sure.
- 12:30SPEAKER_03: So I think one of the key points to make is that it's about selection, who gets selected and what do we worry about?
- 12:36SPEAKER_03: So I think early studies such as the Atlas study, the FLARE study showed demonstrably similar efficacy to oral therapy.
- 12:45SPEAKER_03: When we look at some older studies, what we see concerning long-acting cabitagoviral pivotine is that in terms of efficacy, it was not a barrier to oral therapy.
- 12:55SPEAKER_03: But when we look at the virological failure rate, what we see is that it's higher than would be expected on a modern oral therapy using an intergraze inhibitor.
- 13:04SPEAKER_03: And take the example of the Atlas study, Atlas 2M study, uh, the CVF rate was 1.3%.
- 13:12SPEAKER_03: The important thing to say is that when this happens, it's often accompanied by resistance, sometimes to both classes.
- 13:19SPEAKER_03: So we can see on this slide that there's also an additional publication for some real-world evidence on sort of the first 321 people who were in the opera cohort.
- 13:30SPEAKER_03: And this is the largest US cohort representing about uh the electronic health records of about 12% of the UK population of people living with HIV in the US.
- 13:40SPEAKER_03: And what you can see is very high rates of continuation and 96% maintaining viral suppression.
- 13:48SPEAKER_03: So that's a really uh positive uh sort of overarching uh framing.
- 13:53SPEAKER_03: But what I'd like to talk about is some newer data.
- 13:56SPEAKER_03: So there's more data from the OFRA study, which is which now includes more than a thousand people on monthly uh and two-monthly cabitat of pivarine with a very uh low confirmant virological failure rate, just 14 people out of 10,045 participants.
- 14:11SPEAKER_03: Um, but as I said, when the same finding it keeps occurring, that when there is virological failure, it does tend to happen with resistance, uh, mostly with orpivarine resistance, but sometimes also with integrates inhibitory resistance.
- 14:24SPEAKER_03: But, you know, these findings of you know very good persistence and continuation and the doses being given reliably within the seven-day window are very strong.
- 14:34SPEAKER_03: Uh, and I think you know, it's important to say that this is great to see that the clinical findings are translating uh into the real world uh in with such great fidelity as we are seeing.
- 14:45SPEAKER_04: So I'm gonna ask Anima to kind of think about this as well and go into a little bit more about Cabral Pivorine because not only are we to be fair to the Opera Court, certainly many more people are getting it now than when they first published their data and presented their data.
- 15:00SPEAKER_04: So it is expanding, but we're also expanding it beyond just maybe what was in the original package insert.
- 15:06SPEAKER_04: And now, as the guidelines have indicated, maybe expanding it to folks who um are viremic even and for whom this could be a fantastic benefit.
- 15:15SPEAKER_04: So, do you want to touch on this a little bit as well?
- 15:18SPEAKER_00: There was a study uh that that was uh highlighted at one of our recent conferences in Croix, the Sui Plus study um that looked at individuals who were viremic on oral therapy.
- 15:29SPEAKER_00: Um, many of these individuals had adherence challenges and they were randomized to um switch to immediately to carpet ribivirine or stay on their oral therapy with a permanent endpoint write off at week 24 or six months.
- 15:44SPEAKER_00: And not surprisingly, though, in that study, we find that um individuals um achieved higher rates of virologic suppression for those who were switched to immediate um uh therapy.
- 15:54SPEAKER_00: So for the viral load cutoff of um less than 50 copies per ml, it's about you know mid-70s for cabropyverine, as against just you know under 50% for um individuals who were on oral therapy.
- 16:07SPEAKER_00: And beyond even just the health benefits to the individual for viologic suppression, we know that also suppressing individuals can also have a secondary benefit of mitigating transmission.
- 16:16SPEAKER_00: So I think again, uh this was one study.
- 16:18SPEAKER_00: I'm sure there'll be more data coming down the pike as ongoing clinical trials get reported out, like crown.
- 16:24SPEAKER_00: But again, I think it's now becoming truly established that there could be a life-saving benefit for carbopivirine for the right kind of uh population.
- 16:35SPEAKER_02: Yes, um, so with the latitude um study, so it's it's actually it was actually stopped early because of non-acting capitaline.
- 16:45SPEAKER_02: So clearly uh outperform daily or also be imperable with significant advanced uh challenges.
- 16:54SPEAKER_02: So I think um so this is a real uh real challenges in our traditional uh um thinking.
- 17:03SPEAKER_02: Uh so in the past, we think that so in the patient with wild and suppressed, so they should not switch to the long-acting uh carbo takeaway recovery.
- 17:13SPEAKER_02: But anyway, I think uh so careful patient selection remain very important, particularly uh treatment history and especially in Asia.
- 17:24SPEAKER_02: We uh in the past we have more people, people exposed to in RTI.
- 17:29SPEAKER_02: And also if the patient develops um uh hypothetical recovery system, so it's um so in terms of the the next regimen for the region is very limited because the majority of us we use the uh dolithic area uh-based regimen.
- 17:48SPEAKER_02: And also we have to think about the ability uh for them to return for the injection because it's every um uh one month or two months.
- 17:57SPEAKER_02: So so we have to think about on that as well.
- 18:00SPEAKER_02: So um for me, I think the key message is that rather than repeated, asking the patient to adapt uh to dairy treatment, so we can begin to adapt the treatment uh to the patient.
- 18:14SPEAKER_02: So essentially for those adolescents that have uh very much uh problem with um uh uh adherents.
- 18:25SPEAKER_04: Wonderful.
- 18:25SPEAKER_04: Yeah, so I think this is great.
- 18:26SPEAKER_04: So I think again, we're seeing Cabotegra Pivirine expand to other parts of the world, which is fantastic.
- 18:33SPEAKER_04: I know it's not universal, of course, but we have more and more experience.
- 18:37SPEAKER_04: And so what you said is exactly right in the tailoring.
- 18:39SPEAKER_04: I would mention, of course, we're expanding it to places where there's more hepatitis B.
- 18:43SPEAKER_04: So just being mindful as well in choosing therapies that um do or do not um have activity against hepatitis B is really something to think hard about.
- 18:52SPEAKER_04: And I think I know you think about that a lot.
- 18:55SPEAKER_04: And you mentioned adolescence.
- 18:58SPEAKER_04: And again, as we start to expand caboteropivirine um geographically, we also have to think about this in different populations.
- 19:07SPEAKER_04: And as you mentioned, adolescents really can be a challenging group in which to initiate and maintain antiretroviral therapy and suppress spyremia.
- 19:17SPEAKER_04: So, I mean, there were data recently presented on using CAB ropivarine in adolescence in sub-Saharan Africa.
- 19:25SPEAKER_04: Can you walk us through that?
- 19:28SPEAKER_00: Yeah, thank you, David.
- 19:29SPEAKER_00: And I want to emphasize uh something Ankali said.
- 19:32SPEAKER_00: Again, I think that when we deploy some of these tools, I think they can best serve those who have like this much need.
- 19:38SPEAKER_00: And I think David, you and I work in Liberia, we know that the pediatric HIV cascade generally looks worse than the adult cascade.
- 19:44SPEAKER_00: Um, you know, in some parts of Africa, I mean, like the suppression rates are 30%.
- 19:48SPEAKER_00: I mean, they're very dismal.
- 19:50SPEAKER_00: And we also recognize that adolescents, especially within that 12 to 18 demographic, are clearly a group that clearly needs support with being able to take ART.
- 19:59SPEAKER_00: So it was very heartening to see some data in in actually the context of sub-Saharan Africa.
- 20:05SPEAKER_00: So before countries, Uganda, Kenya, Zimbabwe, and South Africa, and I don't know how they found 476 adolescents to enroll in that study.
- 20:14SPEAKER_00: Um, and it was a randomized trial compared to what they have available, which is TLD, um, uh head-to-head with long-acting injectable capital gabriel pivrine.
- 20:22SPEAKER_00: This was now dosed every eight weeks.
- 20:24SPEAKER_00: We know there's a monthly dosing, this was dosed uh uh bi-monthly.
- 20:27SPEAKER_00: And remarkably, for this group of adolescents, um, you know, long-acting uh cabyverine actually was superior to oral uh TLD, daily TLD for maintaining viral suppression through a two-year period, week uh 96, which I think was absolutely remarkable.
- 20:42SPEAKER_00: Um, not surprisingly, there were no new safety concerns.
- 20:45SPEAKER_00: We know their injective reactions, but as we've seen in adults, these are mostly mild.
- 20:49SPEAKER_00: Um, interestingly, actually non-led to treatment discontinuation in that study, which may be a bit unusual, but again, it's just remarkable to see how adolescents uh tolerated it.
- 20:59SPEAKER_00: And um I know we do say that people who go into studies where an injectable may be offered may be a little more inclined to appreciate that.
- 21:07SPEAKER_00: But again, I think you know, 94% of individuals, adolescents in this study actually said um receiving their eight their injections made uh managing the HIV treatment a lot easier.
- 21:17SPEAKER_00: I always say, even if you correct for a desire to be on these therapies, the number, even if you correct for that, I mean the number is still quite compelling that adolescents enjoyed this uh therapeutic option and reflected, right, in them doing better with their um HIV treatment.
- 21:32SPEAKER_00: So again, I think this data again supports WHO guidance.
- 21:36SPEAKER_00: I know that WHO recommends caviral pyrian as an alternative for maintaining suppression, but we do know that, of course, um, if there were more access and availability, maybe uptake would even be higher.
- 21:47SPEAKER_04: Wonderful.
- 21:48SPEAKER_04: Yeah, so I mean it's in many ways not too surprising.
- 21:53SPEAKER_04: I mean, people get more choices, more options that help fit their preferences, their lifestyles.
- 22:00SPEAKER_04: It works.
- 22:01SPEAKER_04: And it works better than when you don't have options or you're relegated to only the limited selection you had beforehand.
- 22:08SPEAKER_04: So we're going to talk about a newer agent, and that's going to be Lena Caprovir.
- 22:12SPEAKER_04: And we're going to talk about Lena Capavir on and off for a lot of the next part of the session.
- 22:17SPEAKER_04: But again, Anyema, I'm going to tap you because you've been so involved with this.
- 22:21SPEAKER_04: But Lena Capavir, interesting drug, opens lots of opportunities for novel ways of administration.
- 22:29SPEAKER_04: And you have been involved with the Capella study.
- 22:32SPEAKER_04: And now we have longer-term data that were just presented.
- 22:35SPEAKER_04: So, Waukas, again, remind us about Lena Capavir and its starred, of course, in people who were more heavily treatment experienced than some of those that we've been talking about.
- 22:46SPEAKER_00: Yeah, so uh David, I think we can say Lena Capavir is new-ish, no longer new.
- 22:51SPEAKER_00: And we've seen how one compound is now playing like a huge variety of roles from the treatment to prevention spectrum.
- 22:58SPEAKER_00: And so the Cabella study was really looking at Lena Capivare plus an investigator-selected optimized background regimen as a treatment for individuals who are heavily treatment experienced with HIV, who with multidrug resistant HIV virus.
- 23:12SPEAKER_00: So this is now showing the staying power of Lena Capivare over a three-year data.
- 23:18SPEAKER_00: This is a missing equals discluded analysis, right?
- 23:20SPEAKER_00: So people who dropped off for discountations are not included here.
- 23:23SPEAKER_00: But I think it's remarkable for a population that started out with a median C for kind of 150 cells.
- 23:29SPEAKER_00: And we know what that really means for risk for opt-in-scale infections and things that drive more morbidity and mortality among uh individuals with HIV that were not virologically suppressed, uh, to see that three years out for those who had data and stayed on study, about 85% were remained virologically suppressed, is remarkable.
- 23:47SPEAKER_00: And even beyond the virologic suppression, we saw quite significant increases in CD4 counts.
- 23:53SPEAKER_00: And many individuals are lifted out from CD4 counts less than 200 and less than 50, which again uh portends well for their overall health.
- 24:00SPEAKER_00: So I think this is reassuring longer-term data that Lena Capavir, in combination with an optimized background regiment, has done well, was well tolerated, and really was life-saving for this cohort.
- 24:12SPEAKER_04: Yeah, real key.
- 24:13SPEAKER_04: I think this is important data because it really was the proof of concept that Lena Capavier was able to do what we needed it to do and had the staying power and was able to get people in combination with an optimized background suppressed.
- 24:27SPEAKER_04: And that opened up, I think, the door, as we've talked about, and as we're gonna talk about for a little bit more.
- 24:33SPEAKER_04: I think this has become something that at first was okay, this is treatment experience people, this is going to become available, we're gonna find the role for Lena Capri in the future.
- 24:45SPEAKER_04: We're starting to get a glimmer of, and just briefly how how you're thinking about this right now.
- 24:52SPEAKER_03: So, right now, Lena Capavir presents itself in terms of treatment, obviously, as an option for people who have no options, but it also potentially may present itself as an asynchronous partner together with cavitegovia for people for pivotine resistance.
- 25:07SPEAKER_03: And there's been some evidence looking at this, small-scale evidence, and potentially there may be more soon looking at these two drugs combined together until we have sort of synchronous regimens of similar time durations.
- 25:19SPEAKER_03: In the UK, we've had some issues with access for Lenicapavir for uh people with uh highly treatment experienced people.
- 25:26SPEAKER_03: But this is this is resolving now, and we're hoping to be able to use it again because we used it to great effect initially, and then we we lost access, and hopefully we've regained it now.
- 25:36SPEAKER_04: And actually, I don't know about lena capavir availability where you are, but thoughts about that as well?
- 25:42SPEAKER_02: Um it's not really now, but we hope that it will be available soon, since we have the uh linear caprobia access program for the prep um uh program.
- 25:54SPEAKER_02: So I think so with that we can expand to um the uh the treatment.
- 26:00SPEAKER_02: So I think uh one more uh important point is that these real-world data supports the effectiveness of linear caprobia in a much more complex, heavily treatment experience population.
- 26:12SPEAKER_02: That I can say that it's uh it's a lightsaving.
- 26:15SPEAKER_02: Um and also, but however, linear copia still needs to be combined with other active agents.
- 26:23SPEAKER_02: So understanding uh resistance and constructing an effective background regimen remain very important.
- 26:31SPEAKER_04: Yeah, and very exciting.
- 26:32SPEAKER_04: And then Yema, briefly, you know, you presented data on real real-world use of line of cabriar, which I think is fascinating.
- 26:39SPEAKER_04: So, just real briefly, what did you find?
- 26:42SPEAKER_00: Yeah, so David, as you know, right, so the the number of people who were in the Capella study were very small, right?
- 26:48SPEAKER_00: So it was important to us to see how this performed in a much more uh broader population.
- 26:53SPEAKER_00: So this was data from a claims database that covers, I think, up to 90% of people with HIV in the US, just to look at that.
- 26:59SPEAKER_00: And I think a few things struck me, um, again, within the limitations of whatever data you can get from a claims database and incomplete data, et cetera, was that uh in the real world, people are actually using lena capivir off label for individuals who are virtually suppressed, and they're considering other things like intolerance to other medications, um, individuals who are struggling with adherence where the chances of success with oral therapy were kind of low.
- 27:23SPEAKER_00: So, because you can see at baseline, right, uh at the start of lena capivir, about you know mid-30s, we actually had a viral low less than 50.
- 27:31SPEAKER_00: Okay.
- 27:32SPEAKER_00: Um, and that said, so we saw over time that viologic suppression rates for those who are initially on leni-capavir definitely went up.
- 27:38SPEAKER_00: But I think the just the observation of an uh increase in viologic suppression rates in individuals exposed to lenicapivare and over about an 18-month period was interesting.
- 27:48SPEAKER_00: You also see that when you use a viral threshold of less than 200, those numbers jumped to kind of like the mid-80s, suggesting that some individuals had just like low-level viremia, which again could have many reasons.
- 28:00SPEAKER_00: So, again, I think it's remarkable that again, um, leno capivir is being deployed and we're seeing definitely success in the real world.
- 28:07SPEAKER_00: And importantly, um, they find they found that leno capivirus was high so that in different contexts, people are able to deliver these injections on time.
- 28:15SPEAKER_00: Um, but they also found a discontinuation rate about 14%.
- 28:18SPEAKER_00: Um, we didn't really have granular data as to what drove that.
- 28:21SPEAKER_00: So suffice it to say that we are seeing um, you know, some uptick um in the real world and seeing that individuals are enjoying air biologic suppression benefits with um relatively limited discontinuation and uh safety concerns.
- 28:36SPEAKER_04: We're gonna switch gears again to what um no one can argue is not a very new drug, and that's eslatrovir.
- 28:43SPEAKER_04: Um, so eslatrovir, a newer kid on the block, very exciting.
- 28:47SPEAKER_04: So, Chloe, I'm gonna tap you to help walk us through some of the data that we've just seen on Duraverine and Islatrovir, because this is becoming very real for a lot of us, and just understanding a little bit more about some of the clinical trial data that have supported this novel two drug oral regimen.
- 29:08SPEAKER_03: Sure.
- 29:08SPEAKER_03: So um Diraverin uh is an NRTI, Islatravir is an NRTTI, and what we've seen uh presented last year was 48-week data from two phase three randomized controlled studies.
- 29:21SPEAKER_03: Um, one was open label against any oral therapy, and that's the O5-1 study, and then the O5-2 study was compared against BacteGaveria, FTC, and TAF.
- 29:30SPEAKER_03: And both the studies were conducted uh in many, many countries.
- 29:35SPEAKER_03: Um, and then for people who are already virally suppressed, there were randomized two to one to switch to derivaris latravia versus one or the other comparator.
- 29:44SPEAKER_03: And what was found in the open label study is that treatment-related adverse events were a little bit higher, which is what we tend to see in switch studies, which are open label.
- 29:54SPEAKER_03: Um, but there was very, very similar in terms of serious adverse uh events and adverse events leading to discontinuation.
- 30:01SPEAKER_03: So no concerns around uh safety were identified.
- 30:06SPEAKER_03: And importantly, um the efficacy was really excellent.
- 30:10SPEAKER_03: Um, and uh there was nobody in the open label study who developed resistance.
- 30:16SPEAKER_03: So uh it was a really uh positive outcome at week 48.
- 30:19SPEAKER_03: Uh, and then the the other study uh which was looking at with comparing gains back, Tegabra, FTC, and TAF, had very similar findings.
- 30:27SPEAKER_03: Um, but importantly, we didn't see any of the sort of safety, slightly higher safety adverse events because it was not, it was a randomized study, so we didn't see the open label effect.
- 30:37SPEAKER_03: So it was very, very, very similar.
- 30:39SPEAKER_03: Um, something that is quite interesting that's been recently presented is an analysis looking at outcomes for people who had proviral DNA evidence of either N and RTI resistance or the M1A4V or I mutation in the proviral DNA.
- 30:58SPEAKER_03: So they were suppressed, but they had this in proviral DNA.
- 31:01SPEAKER_03: And what was found in this analysis is that having these, having evidence of these uh mutations on proviral DNA did not affect the outcome.
- 31:10SPEAKER_03: So people did just as well, regardless of this.
- 31:13SPEAKER_03: So this was an interesting analysis that was presented uh very recently.
- 31:17SPEAKER_03: Um I think it's also important to say that um at this year's CROI, we saw 96-week data for these two regimens, um, and we saw very similar outcomes uh for um the 05.2 study, comparing against Bictega, FTC, and TAF.
- 31:34SPEAKER_03: Um, for the uh 051 study, uh the people that were originally taking um the standard oral therapy were switched over onto to receive doraverous latera at that time point.
- 31:47SPEAKER_03: So we saw an additional group of people receiving doravenous latera, uh, and their findings were very, very similar to the original cohort.
- 31:54SPEAKER_03: So, you know, every very very unsurprising, everything exactly as it says on the tin.
- 31:59SPEAKER_03: And also uh the CE4 count uh and total lymphocyte counts were absolutely stable and fine.
- 32:06SPEAKER_03: So all I can say is you know, very positive findings uh with no safety concerns.
- 32:14SPEAKER_02: Yeah, I think um so the legitimate is is good in terms of uh efficacy, but we have to think about um uh about the hepatitis B.
- 32:26SPEAKER_02: So in in Asia where hepatitis B coinfection is really common.
- 32:32SPEAKER_02: So whenever we simplify ART by removing, so we need to confirm hepatitis B system and ensure that those with hepatitis B remain on hepatitis B.
- 32:44SPEAKER_02: So this is very important for Asia and also for those who are not immune to uh to hepatitis B.
- 32:51SPEAKER_02: So vaccination to be offered.
- 32:54SPEAKER_02: So the the key message for me is that simplify HIV treatment without compromising hepatitis B prevention and management.
- 33:04SPEAKER_02: Yeah.
- 33:05SPEAKER_04: So Chloe, you're in a role, so I'm gonna ask you to help us as well in talking about uh yet another new combination.
- 33:12SPEAKER_04: I said it's gonna, we're gonna snack from different bowls and we're coming back to Lena Caprevere, but this time with an integrace back to integrace.
- 33:20SPEAKER_04: So Bictegraveer plus Lena Capravir, the artistry trials.
- 33:24SPEAKER_04: So what's going on here?
- 33:26SPEAKER_04: Can you walk us through that?
- 33:28SPEAKER_03: Sure.
- 33:29SPEAKER_03: So this is a new daily oral therapy, and this uh has been studied in a phase three trial program.
- 33:37SPEAKER_03: And there were two studies.
- 33:38SPEAKER_03: The R31 study is a really, really interesting study, which involved uh what they considered to be a complex population.
- 33:47SPEAKER_03: And complex really means complex.
- 33:49SPEAKER_03: It meant people uh who were on twice-daily drugs in 40% of cases, people who were on three different types of drugs, people that were taking, you know, protease inhibitors.
- 34:01SPEAKER_03: And uh I think the other thing to say is that many of the participants had other comorbidities, so they had other significant medical problems, particularly cardiovascular problems, were taking lots of other medications.
- 34:13SPEAKER_03: So there was a real need to simplify therapy and to remove drugs such as retonovia boosting or COB cystat boosting that can really lead to liabilities, particularly with drug-drug interactions.
- 34:26SPEAKER_03: So the findings were really pretty stellar in this population, uh, in that it was non-inferior to maintaining the oral regimen, the standard oral oral therapy regimen that they were taking, their complex regimen.
- 34:39SPEAKER_03: There were no emergent treatment resistance.
- 34:42SPEAKER_03: So that was very important.
- 34:44SPEAKER_03: And the uh safety and tolerability were very good.
- 34:47SPEAKER_03: Uh, there was nothing of concern.
- 34:50SPEAKER_03: You know, as Anthony has pointed out, you know, hepatitis B reactivation or new infections are an issue for any uh Tinofovia free regimen.
- 34:58SPEAKER_03: That is just a simple fact.
- 35:00SPEAKER_03: So there was a second study, which was called Artistry II.
- 35:04SPEAKER_03: This was in a slightly younger population, around sort of five 45 years of age.
- 35:09SPEAKER_03: They also had some comorbidities.
- 35:11SPEAKER_03: And this was a blinded study comparing against bictegroviral FDC and TAF.
- 35:15SPEAKER_03: Once again, there was non-inferiority.
- 35:17SPEAKER_03: But in one, in this study, there was one person uh with uh an emergent um integrase inhibitor mutation, no capsid mutations.
- 35:26SPEAKER_03: And this is someone who had previously taken an early integrated inhibitor rel tegovir and also had taken previous Dolly tegovir.
- 35:34SPEAKER_03: Um, so that was you know pretty much a summary, but very uh very good safety outcomes in both studies.
- 35:41SPEAKER_03: And once again, no signal around CD4 count and total lymphside count.
- 35:46SPEAKER_04: Wonderful.
- 35:46SPEAKER_04: Thank you.
- 35:47SPEAKER_04: That is really helpful and it is exciting, and I think again, this raises options for people who may need or desire some switching from more complex regimens, whether it be in the number of molecules that they're taking or the number of pills or the frequency or other complexities.
- 36:03SPEAKER_04: So I think this really was helpful in thinking about this again, pretty novel combination.
- 36:10SPEAKER_04: So I'm gonna switch gears completely to now talk about.
- 36:14SPEAKER_04: We talked about Islatrovir with Diravering, we're talking about Lenicapavir with Big Tegravir.
- 36:19SPEAKER_04: Now we're gonna talk about Islatrovir and Lenicapavir.
- 36:22SPEAKER_04: And not only that, but we're gonna be talking about them orally once weekly.
- 36:27SPEAKER_04: Um and I'm gonna now tap on Yema to help us with this because this was probably one of the bigger, I think, um, attention grabbers at the IAS conference in Rio.
- 36:37SPEAKER_04: And really interesting data and some of the first data we've seen about this once-weekly oral combination to treat HIV.
- 36:46SPEAKER_04: So um what give us an overview, Ngema.
- 36:51SPEAKER_00: Thank you, David.
- 36:52SPEAKER_00: So let's start, let's start with the phase two data.
- 36:54SPEAKER_00: But initially the regimen construct, right?
- 36:56SPEAKER_00: So, like Chloe's mentioned for the orb door ISO program, ISO is a novel NRTTI, um, a little bit differentiated from other NRTIs regarding resistance pathway, all those vulnerable to M184B and TAMS.
- 37:08SPEAKER_00: Um, and the Lenacapper Vaya, which is a novel caps inhibitor.
- 37:11SPEAKER_00: I mean, they're combined together because of their uh pharmacokinetic uh properties that allow them to be dosed as a weekly uh oral therapy.
- 37:19SPEAKER_00: I mean, we've seen from surveys for uh for people with HIV that desire for long-acting therapies, right?
- 37:25SPEAKER_00: And I think, at least hypothetically, um, trying to explore if weekly therapy um you know could do better than data therapy or be as good um regarding uh adherence and being able to keep people on treatment.
- 37:38SPEAKER_00: So this is again the phase two study looked at individuals.
- 37:41SPEAKER_00: I want to highlight key important things, like these are people who did not have a history of virologic failure, they had a threatening clearance of at least 30 or higher, and did not have hepatitis B.
- 37:51SPEAKER_00: And this compared uh randomized trial compared isoland to daily oral therapy.
- 37:57SPEAKER_00: I think it was remarkable through 96 weeks, so two years, that there were actually no confirmed virologic failure or treatment emergent resistance in either arms in the study.
- 38:07SPEAKER_00: Again, uh, once weekly looking as good as once daily oral therapy.
- 38:11SPEAKER_00: So the phase two data was really, really compelling, David.
- 38:14SPEAKER_00: And of course, you know this since been uh phase three data um that have uh followed this.
- 38:20SPEAKER_00: So um again, uh for the phase three data, we know that there were two studies, um, island one and island two.
- 38:27SPEAKER_00: Island one was the RCT with Len Islatvier going head to head with Big TAF FTC, and island two was a randomized study looking at uh Len Islatrevere um head to head with any standard daily um oral therapy.
- 38:40SPEAKER_00: And like you rightly said, David, these were some of the highlights of the presentations.
- 38:44SPEAKER_00: I think one of them was a co-chair choice at IES 2026.
- 38:48SPEAKER_00: And again, both of these studies showed that ISO LEN was non-inferior to uh comparative arms at week 48 with suppression rates uh in the mid-90s, which was remarkable.
- 38:58SPEAKER_00: And again, we still do not see a treatment emergent resistance to LEN ISO in the study.
- 39:04SPEAKER_00: Again, remarkable.
- 39:05SPEAKER_00: There were over 1,200 participants in the entire ISLEND clinical trial program, which I think was just absolutely uh remarkable.
- 39:13SPEAKER_00: Um important to highlight again that um the uh patient-reported outcome assessments within those studies again show, again, granted, the caveat that people going to those studies know that they may receive a long acne therapy, but again, individuals definitely express an overwhelming preference for weekly therapy above oral.
- 39:30SPEAKER_00: And from a clinical standpoint, I will say um providers have been concerned about uh people with HIV being able to take a new treatment paradigm, which is take a pill every week.
- 39:40SPEAKER_00: We found adherence rates like almost hitting 99% in this latravural and a capivar arm.
- 39:45SPEAKER_00: So people were able to take these um drugs um as prescribed, which I think was absolutely remarkable, very minimal um adherence support in the study.
- 39:55SPEAKER_00: So these studies are very compelling.
- 39:56SPEAKER_00: This will go for regulatory submission, and I think this might end up being the first weekly oral therapy available to our the people we care for.
- 40:05SPEAKER_02: Yeah, so so what I find particularly attractive is that innovation does not necessarily have to mean injection.
- 40:14SPEAKER_02: So this is very important for resource-limited setting that so if we can use once weekly oral ART.
- 40:21SPEAKER_02: So it could reduce treatment burden without requiring the infrastructure needed for long-acting injectable.
- 40:29SPEAKER_02: So for both uh the burden for both the patient and for the the uh HIV clinic or in uh or at the hospital.
- 40:37SPEAKER_02: So this uh may be particularly relevant in a resource limited setting.
- 40:42SPEAKER_02: So um so we hope that so the the this novel uh regimen can expand to resource limited setting really soon.
- 40:54SPEAKER_04: Yeah, wonderful.
- 40:56SPEAKER_04: And Chloe, you as well, thinking about this and and where you can see this going.
- 41:01SPEAKER_03: Yeah, so I do have some thoughts here.
- 41:03SPEAKER_03: I mean, I think I've wondered whether the sense of freedom and sort of the removal of daily reminder and disclosure concerns, which is what people feel relieved by with the long-acting injectable, would be as prominent with the weekly oral therapy and whether it would provide that level of relief to people around disclosure concerns and a sense of daily reminder of status.
- 41:25SPEAKER_03: And I was very interested in the patient reported outcome data, which was presented in the island two study because it was um an open label study.
- 41:34SPEAKER_03: Um and what they reported was treatment satisfaction, which was high.
- 41:39SPEAKER_03: It was sort of around 80%, you know, very satisfied or satisfied.
- 41:43SPEAKER_03: Um, not quite as high as we've seen, you know, when it's over 90% with injectables, although it's not comparable.
- 41:49SPEAKER_03: Um, but what they did talk about is reduction in burden of taking pills.
- 41:55SPEAKER_03: That was a different measure that that haven't seen used before.
- 41:58SPEAKER_03: And the the sense of reduced burden of taking pills was very high for the people that switched to the weekly oral therapy.
- 42:05SPEAKER_03: So it was more around more than 60% found found a reduction in burden.
- 42:09SPEAKER_03: So I think that's very hopeful.
- 42:11SPEAKER_03: And I think we do need to understand more from people living with HIV.
- 42:14SPEAKER_03: We need to see some qualitative data now from the study, and there was an interview study, and also from other investigators, you know, really trying to understand, you know, what this brings to the person in terms of the freedom that injectables provide, although they are very challenging from a capacity perspective.
- 42:32SPEAKER_03: Um, this was a very this is a very important issue for me.
- 42:35SPEAKER_04: You know, again, even something that could help meet that need that we're talking about and aspire to.
- 42:42SPEAKER_04: There's been a lot of discussion, and this is now talking more further off in the future of could we come up with something that could be given with Lena Capavir, as we talked about before, which is administered every six months subcutaneously, and which we saw in Capella and in the real world data that Anyema discussed can be used basically for people who are heavily treatment experienced.
- 43:04SPEAKER_04: Could this become something that could become much more widely available to treat HIV if it had a dance partner?
- 43:10SPEAKER_04: Um, and so you need something else that could be given every six months.
- 43:14SPEAKER_04: And broadly neutralizing antibodies do have a long half-life, and there's been a lot of work done over the last decade trying to understand how to use these.
- 43:23SPEAKER_04: And now with this potential combination of lano capavir plus a cocktail of broadly neutralizing antibodies, again, theoretically, you can start to see that there's some daylight for an every six-month regimen.
- 43:37SPEAKER_04: And again, I'm gonna ask you again to kind of help us walk through this because you've thought a lot about this and been involved with this and presented these data.
- 43:44SPEAKER_04: But where are we now in thinking about broadly neutralizing antibodies and Lenic Capier and some of the data that we've most recently seen?
- 43:53SPEAKER_00: Yeah, David.
- 43:54SPEAKER_00: So I think the field is struggling to figure out where BNAP sits between the arsenal of Tools we use again across the spectrum of treatment and prevention.
- 44:03SPEAKER_00: And as you know, these are also being evaluated for at least functional cure approaches for HIV.
- 44:10SPEAKER_00: I think, again, just given the timing of when this study was developed, I think the real driver for this study was to try to put things together that shared similar pharmacokinetic properties.
- 44:20SPEAKER_00: So they could be at least those twice a year.
- 44:22SPEAKER_00: I think that's the strongest argument.
- 44:24SPEAKER_00: Again, so this was then combining two antibodies with non-overlapping mechanism action profiles or binding site profiles to optimize breath in combination with a small molecule antiviral to try to uh have people maintain suppress a little bit of differences between the dosing lenicapivaire being the sub Q and the BNAPs being administered and infusion.
- 44:48SPEAKER_00: So again, these were some of the early uh proof of concept studies looking to see if lenacapivare with two burden neutralizing antibodies, one is called teropavimab and cellervimab, um, giving together every six months for maintenance of rhyologic suppression.
- 45:03SPEAKER_00: So um in this study um as shown, um lenicapiver was combined with these two BNABs.
- 45:09SPEAKER_00: Um people were randomized to go on that, or stay understand all therapy was a two-to-one uh randomization.
- 45:15SPEAKER_00: And we found that after one year of follow-up that um there were high rates of rhyologic suppression in those who were in the LEN BNAB arm.
- 45:23SPEAKER_00: Again, this was not really part for efficacy, but just to really look at the numbers as they went along.
- 45:28SPEAKER_00: Um in the LEN BNAP arm, there were three individuals that met viral uh rebound criteria in different instances, and some of those was very, very low level of iremia, but I think it at least um met the proof-of-concept uh determination that um it appears that these are able to successfully uh keep um individuals suppressed.
- 45:48SPEAKER_00: Uh, we did find that um individual, the three individuals who had some viral rebound did have higher body weights of grade 100 kilogram.
- 45:56SPEAKER_00: So the dose um of the BNAP was adjusted to uh try to result in higher exposures for those individuals as well.
- 46:04SPEAKER_00: Sites were able to administer these, and they were, you know, the safety profile looked pretty okay with no um severe adverse events and no infusion-related reaction.
- 46:14SPEAKER_00: So um, this program will be moving into phase uh three, which we're excited about, and I think we need to stay tuned for that.
- 46:22SPEAKER_04: Well, we talked about a lot of different stuff, and I think it is just this incredibly expanding landscape with emerging uh novel agents, sometimes coupled with older agents, sometimes coupled with other newer agents.
- 46:37SPEAKER_04: And I think it is moving quickly, and there's mixing and matching to be creative, and I think that's wonderful.
- 46:42SPEAKER_04: I think that's great.
- 46:43SPEAKER_04: And so we know generally we're moving away from daily oral therapy.
- 46:48SPEAKER_04: You know, we're seeing penetration of some of the newer novel agents and combinations um in different parts of the world.
- 46:55SPEAKER_04: That's something we have to keep an eye on and keep advocating for.
- 46:59SPEAKER_04: We need to make sure all of us uh in this discussion have access to the same medication so we're all our patients can all benefit um equally.
- 47:07SPEAKER_04: I think that's really key, and I think we all agree with that.
- 47:10SPEAKER_04: So again, we're we're moving in all sorts of different ways that I think many of us couldn't have predicted, even just a few short years ago.
- 47:17SPEAKER_04: And it is exciting, but we have to keep our eye on the prize and just make sure that we have regimens, uh, a slew of regimens that are available for people all over, and that they can access them and that they're safe and effective, and that we understand with our patients the decisions that they are making and the implications for them and help navigate them through that.
- 47:37SPEAKER_04: So you guys have done a great job of helping bring us home.
- 47:41SPEAKER_04: I'm gonna end with a quote from Angelina Namiba.
- 47:45SPEAKER_04: She is a person living with HAV for three decades, a mom and an advocate.
- 47:53SPEAKER_01: You know, I do like the idea of having those new and emerging options, actually.
- 47:58SPEAKER_01: Because, like everything else, whether it's prevention or treatment, the more options people have, the more likely they are to be able to uptake one of them and that the one and one that really works for them.
- 48:09SPEAKER_01: And so I think for me, having long-acting injectables is really important.
- 48:14SPEAKER_01: We've been having long-acting injectables for other things, you know, for example, contraceptives, you know?
- 48:19SPEAKER_01: So why not HIV?
- 48:23SPEAKER_04: So I'm I'm gonna ask each of you in turn to just reflect on that um real quickly, and then we'll close out.
- 48:29SPEAKER_04: So Chloe, I'm gonna start with you.
- 48:32SPEAKER_03: I I don't think anyone could have said it better than Angelina.
- 48:35SPEAKER_03: It's all about choice and it's all all about having options that um address people's specific needs.
- 48:41SPEAKER_03: It's about personalizing medicine.
- 48:44SPEAKER_03: Um and the future is bright, but it needs to be bright for everybody, uh, no matter where you live.
- 48:50SPEAKER_04: Wonderful.
- 48:52SPEAKER_02: Angela, so um I think so the virus of patient tell us that a rhythm is working biologically, but listen to the patient tell us whether their resume is truly working for their life.
- 49:09SPEAKER_04: And then Yemer.
- 49:11SPEAKER_00: Yeah, I feel um that the pipeline is really addressing on met needs with HIV treatment.
- 49:17SPEAKER_00: I like that we're being very thoughtful about people not that are not being best served by the current therapeutics we have and thinking about adjusting dosing frequencies and way we administer these drugs to be able to try to expand who is virologically suppressed.
- 49:31SPEAKER_00: I like that we're praying for the future for things like integrated resistance, and I like that we're trying to meet treatment for people who've had long treatment history and treat mutations, and being able to offer a single pill like BitLin, for example, for those individuals, I think is transformational.
- 49:46SPEAKER_04: Wonderful.
- 49:47SPEAKER_04: Thank you for those hopeful and encouraging messages and for all the work that you've been doing and for participating today and in walking us through a pretty complex landscape.
- 49:57SPEAKER_04: Here are for all of you some additional lived experience insights.
- 50:50SPEAKER_04: So thanks again.
- 50:52SPEAKER_04: We've developed practical resources called clinical points, and this is for clinicians and people seeking information on HIV.
- 51:01SPEAKER_04: These tools can support conversations and making decisions like we've talked about today, and are available within this activity and through CME Outfitters Hub.
- 51:13SPEAKER_04: Let's conclude by translating today's discussion into SMART goals.
- 51:17SPEAKER_04: These are goals that are specific, measurable, attainable, relevant, and timely.
- 51:24SPEAKER_04: Consider how you might apply these in your practice.
- 51:27SPEAKER_04: Integrate the latest long-acting and oral simplification trial data into current and future shared decision-making conversations with your eligible patients.
- 51:37SPEAKER_04: Identify patients on complex or multi-drug regimens who may be candidates for once daily or long-acting simplification strategies when they become available in your region.
- 51:48SPEAKER_04: And incorporate the healthcare provider and patient clinical point resources that are available on Infectious Disease Hub into your next patient conversation to support shared decision making about emerging HIV treatment options.
- 52:03SPEAKER_04: Also, check out the additional resources located on the CME Outfitters website.
- 52:10SPEAKER_04: And again, visit CME Outfitters Infectious Disease Hub for resources for both healthcare professionals and people seeking information on HIV.
- 52:20SPEAKER_04: This CME Outfitter snack is part of a four-program series featuring global HIV experts.
- 52:26SPEAKER_04: We hope you'll explore the other short focused activities.
- 52:30SPEAKER_04: To receive credit for today's program, please complete a post test and evaluation.
- 52:36SPEAKER_04: You'll then be able to download and print your certificate.
- 52:39SPEAKER_04: Thank you to our faculty for sharing their experience and regional perspectives, and thank you to our audience for your continued commitment to improving testing, linkage, and care for people living with HIV.
- 52:50SPEAKER_04: Goodbye.